171 related articles for article (PubMed ID: 37713832)
21. SPON2 Is Upregulated through Notch Signaling Pathway and Promotes Tumor Progression in Gastric Cancer.
Kang HG; Kim WJ; Noh MG; Chun KH; Kim SJ
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32492954
[TBL] [Abstract][Full Text] [Related]
22. An integrative pan-cancer analysis reveals the oncogenic role of mutS homolog 6 (MSH6) in human tumors.
Zhan H; Mo F; Xu Q; Wang S; Zhang B; Liu X; Dai M; Liu H
Aging (Albany NY); 2021 Dec; 13(23):25271-25290. PubMed ID: 34941572
[TBL] [Abstract][Full Text] [Related]
23. SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin-Rho GTPase-Hippo Pathways.
Zhang YL; Li Q; Yang XM; Fang F; Li J; Wang YH; Yang Q; Zhu L; Nie HZ; Zhang XL; Feng MX; Jiang SH; Tian GA; Hu LP; Lee HY; Lee SJ; Xia Q; Zhang ZG
Cancer Res; 2018 May; 78(9):2305-2317. PubMed ID: 29440144
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
Liu P; Wang X; Pan L; Han B; He Z
Front Immunol; 2022; 13():901784. PubMed ID: 35720327
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of SPON2 inhibits the growth of triple-negative breast cancer.
Hu X; Su C; Wei J
Front Oncol; 2023; 13():1141417. PubMed ID: 36959811
[TBL] [Abstract][Full Text] [Related]
26. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
[TBL] [Abstract][Full Text] [Related]
27. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Analysis of Prognostic and Immune Infiltrates for RAD51 in Human Breast Cancer.
Li F; Zhang Y; Shi Y; Liu S
Crit Rev Eukaryot Gene Expr; 2021; 31(4):71-79. PubMed ID: 34587437
[TBL] [Abstract][Full Text] [Related]
29. Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma.
Wang Z; Zheng W; Chen Z; Wu S; Chang H; Cai M; Cai H
Front Oncol; 2022; 12():1055376. PubMed ID: 36531056
[TBL] [Abstract][Full Text] [Related]
30. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
31. Spondin2 is a new prognostic biomarker for lung adenocarcinoma.
Yuan X; Bian T; Liu J; Ke H; Feng J; Zhang Q; Qian L; Li X; Liu Y; Zhang J
Oncotarget; 2017 Aug; 8(35):59324-59332. PubMed ID: 28938639
[TBL] [Abstract][Full Text] [Related]
32. Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer.
Chen J; Gao G; Li L; Ding J; Chen X; Lei J; Long H; Wu L; Long X; He L; Shen Y; Yang J; Lu Y; Sun Y
Front Genet; 2022; 13():817118. PubMed ID: 35601500
[No Abstract] [Full Text] [Related]
33. The Comparison Spondin 2 Levels in Primary Glomerular Diseases.
Kahvecioglu S; Ersoy A; Üstundag Y; Ayar Y; Gül CB; Yildiz A; Esen SA; Dogan I; Oruc A
Saudi J Kidney Dis Transpl; 2020; 31(5):1014-1024. PubMed ID: 33229764
[TBL] [Abstract][Full Text] [Related]
34. Identifying the role of NUDCD1 in human tumors from clinical and molecular mechanisms: a study based on comprehensive bioinformatics and experimental validation.
Han B; He J; Chen Q; Yuan M; Zeng X; Li Y; Zeng Y; He M; Feng D; Ma D
Aging (Albany NY); 2023 Jun; 15(12):5611-5649. PubMed ID: 37338527
[TBL] [Abstract][Full Text] [Related]
35. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer.
Li K; Wang Q; Bian H; Chen Z; He H; Zhao X; Gong P
Front Mol Biosci; 2022; 9():886904. PubMed ID: 35836933
[No Abstract] [Full Text] [Related]
37. Tumor-derived exosomal HOTAIRM1 regulates SPON2 in CAFs to promote progression of lung adenocarcinoma.
Chen Z; Bian C; Huang J; Li X; Chen L; Xie X; Xia Y; Yin R; Wang J
Discov Oncol; 2022 Sep; 13(1):92. PubMed ID: 36153414
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
39. A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.
Zhou M; Chen Y; Gu X; Wang C
Pathol Oncol Res; 2022; 28():1610504. PubMed ID: 36061144
[No Abstract] [Full Text] [Related]
40. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
